The news release below is nearly two weeks old, but it is still highly pertinent – and consistent with a CC on August 7th where a 400% increase in antenna sales was announced for the 90 days prior to August (mostly in the final FQ, which ended Aug 31). This amounted to approximately 300 antennas used in three months. The “antennas” are an approximately $2000 disposable item; and up to three are used for each procedure. In addition, each one-time rental of the MTX-itself brings a “very handsome” fee (pays for the mfg costs in only three uses! – according to CEO Wolcott).
This is a game-changing product, folks! For the large and rapidly-growing Interventional Oncology (IO) market, the MTX-180 is a breakthrough product: greatly improved efficacy, precision, safety, and ease of use. It can reasonably be expected to garner the major share of the (present) several-billion-$ IO market. Bear in mind that it is still early in the introductory phase for the fee-per-use (FPU) program for the MTX-180 product line. To date, the market has only been slightly penetrated.
http://investor.bsdmedical.com/press-release/results-operations-and-corporate-announcements/bsd-medical-reports-significant-quarter
BSD Medical Reports Significant Quarterly Growth of MicroThermX® Microwave Ablation System Sales and Equipment Utilization
Category: Results of Operations and Corporate Announcements, Sales
Thursday, December 6, 2012 7:00 am MST
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today a 586% increase in sales for the MicroThermX®Microwave Ablation System (MicroThermX®) product line for the fiscal quarter ended November 30, 2012, as compared to the fiscal quarter ended November 30, 2011. Disposable SynchroWave antennas were a significant portion of these sales, reflecting the success of the Company's fee-per-use equipment rental program and increasing sales of MicroThermX® equipment. This is a dramatic increase in sales for MicroThermX® products and representative of a continuing trend of accelerating MicroThermX® revenue.
BSD's current focus is to increase MicroThermX® revenues by expanding the fee-per-use equipment rental program and increasing direct sales support in major U.S. metropolitan areas. These programs continue to produce very successful results, and the current fiscal year promises to provide continuing growth in revenues from the MicroThermX®products. The MicroThermX® introduced into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, providing an important ongoing revenue stream.
About the MicroThermX® Microwave Ablation System
The MicroThermX® Microwave Ablation System is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX®introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System, which allows BSD to market the MicroThermX® system in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX® to a number of international markets. |
